Radiation therapy strategies and clinical trials in pediatric Ewing’s sarcoma

详细信息    查看全文

• 作者：Paul J. Chuba (1)
  
• 关键词：Ewing sarcoma family of tumors ; Intergroup Ewing Sarcoma Studies ; Pediatric Ewing’s sarcoma
• 刊名：Journal of Radiation Oncology
• 出版年：2013
• 出版时间：June 2013
• 年：2013
• 卷：2
• 期：2
• 页码：149-158
• 全文大小：402KB
• 参考文献：1. Hense HW, Ahrens S, Paulussen M et al (1999) Descriptive epidemiology of Ewing’s tumor: analysis of German patients from (EI)CESS 1980-997. Klin Paediatr 21:271-75 CrossRef
  2. Dunst J, Schuck A (2004) Role of Radiotherapy in Ewing Tumors. Pediatr Blood Cancer 42:465-70 CrossRef
  3. Paulino AC, Nguyen TX, Mai WY (2007) An analysis of primary site control and late effects according to local control modality in non-metastatic Ewing sarcoma. Pediatr Blood Cancer 49:423-29 CrossRef
  4. Karosas A (2010) Ewing’s Sarcoma. Am J Health Syst Pharm 67:1599-605 CrossRef
  5. Ewing J (1922) The mode of action of radiation upon carcinoma. Am J Roentgenol 9:331-36
  6. Ewing J (1921) Diffuse endothelioma of bone. Proc NY Pathol Soc 21:17-4
  7. Ewing J (1917) Radium therapy in cancer. J Am Med Assoc 68:1238-247 CrossRef
  8. Ewing J (1926) Tissue reactions to radiation. Am J Roentgenol 15:93-15
  9. Ewing J (1930) Factors determining radioresistance in tumors. Radiology 14:186-90
  10. Ewing J (1934) American Radium Society Janeway lecture excerpts. Am J Roentgenol 31:153-63
  11. LeDeley MC, Delattre O, Schaefer KL et al (2010) Impact of EWS-ETS fusion type on disease progression in Ewing’s sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-EWING 99 Trial. J Clin Oncol 28:1982-988 CrossRef
  12. Van Doorminck JA, Ji L, Schoab B et al (2010) Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol 28:1989-994 CrossRef
  13. Zoubek A, Dockhorn-Dwomiczak B, Dlattre O et al (1996) Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 14:1245-251
  14. De Alava E, Kawai A, Heley JH et al (1998) EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing’s sarcoma. J Clin Oncol 16:1248-255
  15. Barr FG, Meyer WH (2010) Role of fusion subtype in Ewing sarcoma. J Clin Oncol 28:1973-981 CrossRef
  16. Nesbit ME et al (1990) Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the first intergroup study. J Clin Oncol 7:1664-674
  17. Burgert EO Jr et al (1990) Multimodal therapy for the management of nonpelvic localized Ewing’s sarcoma of bone: Intergroup Study IESS-II. J Clin Oncol 8:1514-524
  18. Evans RG et al (1991) Multimodal therapy for the management of localized Ewing’s sarcoma of pelvic and sacral bones: a report from the second intergroup study. J Clin Oncol 9:1173-180
  19. Cangir A et al (1990) Ewing’s sarcoma metastatic at diagnosis: results and comparison of two Intergroup Ewing’s sarcoma studies. Cancer 66:887-93 CrossRef
  20. Merchant TE, Kushner BH, Sheldon JM, LaQuaglia M, Healey JH (1999) Effect of low-dose radiation therapy when combined with surgical resection for Ewing sarcoma. Med Pediatr Oncol 33:65-0 CrossRef
  21. Grier HE, Krailo MD, Tarbell NJ et al (2003) Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. NEJM 348:694-01 CrossRef
  22. Granowetter L, Womer R, Devidas M, Krail M et al (2009) Dose-intensified compared with standard chemotherapy for non-metastatic Ewing sarcoma family of tumors: a Children’s Oncology Group study. J Clin Oncol 27:2536-541 CrossRef
  23. Donaldson SS et al (1989) The Pediatric Oncology Group (POG) experience in Ewing’s sarcoma of bone. Med Pediatr Oncol 17:283
  24. Schuck A, Ahrens S, Paulussen M et al (2003) Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys 55:168-77 CrossRef
  25. Dunst J, Jurgens H, Sauer R et al (1995) Radiation therapy in Ewing’s sarcoma: an update of the CESS 86 trial. Int J Radiat Oncol Biol Phys 32:919-30 CrossRef
  26. Dunst J, Sauer R, Burgers JM et al (1991) Radiation therapy as local treatment in Ewing’s sarcoma: results of the cooperative Ewing’s sarcoma studies CESS 81 and CESS 86. Cancer 67:2818-825 CrossRef
  27. Jurgens H, Exner U, Gardner H et al (1988) Multidisciplinary treatment of primary Ewing’s sarcoma of bone: a 6-year experience of a European cooperative trial. Cancer 61:23-2 CrossRef
  28. Schuck A, Ahrens S, Konarzewska A et al (2002) Hemithorax irradiation for Ewing tumors of the chest wall. Int J Radiat Oncol Biol Phys 54:830-38 CrossRef
  29. Paulussen M, Craft AW, Lewis I et al (2008) Results of the EICESS-92 study: two randomized trials of Ewing’s sarcoma treatment—cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 26:4385-393 CrossRef
  30. Schuck A, Ahrens S, Von Schorlemer I et al (2005) Radiotherapy in Ewing tumor of the vertebrae: treatment results and local relapse analysis of the CESS 81/86 and EICESS 92 trials. Int JRadiat Oncol Biol Phys 63:1562-567 CrossRef
  31. Indelicato DJ, Keole SR, Shahlahee AH et al (2008) Impact of local management on long-term outcomes in Ewing tumors of the pelvis and sacral bones: the University of Florida experience. Int J Radiat Oncol Biol Phys 72:42-8
  32. Indelicato DJ, Keole SR, Shahlahee AH et al (2008) Long-term clinical and functional outcomes after treatment for localized Ewing’s tumor of the lower extremity. Int J Radiat Oncol Biol Phys 70:501-09 CrossRef
  33. Whaley JT, Indelicato DJ, Morris CG et al (2010) Ewing tumors of the head and neck. Am J Clin Oncol 33:321-25 CrossRef
  34. Paulussen M, Ahrens S, Burdach S et al (1998) Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. Ann Oncol 9:275-81 CrossRef
  35. Paulussen M, Ahrens S, Craft AW et al (1998) Ewing’s tumors with primary lung metastases: survival analysis of 114 (European Intergroup) cooperative Ewing’s sarcoma Studies patients. J Clin Oncol 15:3044-052
  36. Spunt SL, McCarville MB, Kun LE et al (2001) Selective use of whole-lung irradiation for patients with Ewing sarcoma family tumors and pulmonary metastases at the time of diagnosis. J Pediatr Hematol Oncol 23:93-8 CrossRef
  37. Paulino AC, Mai WY, Teh BS (2012) Radiotherapy in metastatic Ewing’s sarcoma. Am J Clin Oncol (Epub ahead of print)
  38. Ellis R (1961) The distribution of active bone marrow in the adult. Phys Med Biol 5:255-58 CrossRef
  39. Baeza MR, Barkley HT Jr, Fernandez CH (1975) Total-lung irradiation in the treatment of pulmonary metastases. Radiology 116:151-54
  40. Felgenhauer JL, Nieder ML, Krailo MD et al. (2012)A pilot study of low-dose antiangiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: a Children’s Oncology Group (COG) phase II study (Epub ahead of print)
  41. Crew JP, Jephcott CR, Reynard JM (2001) Radiation-induced haemorrhagic cystitis. Eur Urol 40:111-23 CrossRef
  42. Stillwell TJ, Benson RC Jr, Burgert EO Jr (1988) Cyclophosphamide-induced hemorrhagic cystitis in Ewing’s sarcoma. J Clin Oncol 6:76-2
  43. Bryant BM, Jarman M, Ford HT et al (1980) Prevention of isophosphamide induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet 2:657-9 CrossRef
  44. Chuba PJ, Hamre MR, Thomas R et al. (2005) Radiation induced second sarcomas occurring after primary sarcoma of childhood. (abstract) Proceedings of Pediatric Radiation. Oncology Society (PROS), Lyon.
  45. Kuttesch JF, Wexler LH, Marcus RB et al (1996) Second malignancies after Ewing’s sarcoma. Radiation dose-dependency of secondary sarcomas. J Clin Oncol 14:2818-825
  46. Goldsby R, Burke C, Nagarajan R et al (2008) Second solid malignancies among children, adolescents, and young adults diagnosed with malignant bone tumors after 1976: follow-up of a Children’s Oncology Group Cohort. Cancer 113:2597-604 CrossRef
  47. Paulussen M, Ahrens S, Lehnert M et al (2001) Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Ann Oncol 12:1619-630 CrossRef
  48. Rombi B, Delaney T, Macdonald S et al (2012) Proton radiotherapy for pediatric Ewing’s sarcoma: initial clinical outcomes. Int JRadiat Oncol Biol Phys 82:1142-148 CrossRef
  49. Burke MJ, Walterhouse DO, Jacobsohn DA et al (2007) Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors. Pediatr Blood Cancer 49:196-98 CrossRef
  50. Burdach S, van Kaick B, Laws HJ et al (2000) Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-cell transplant programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna Austria. Ann Oncol 11:1451-462 CrossRef
  51. Hawkins D, Barnett T, Bensinger W et al (2000) Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors. Med Pediatr Oncol 34:328-37 CrossRef
  52. Kushner BH, Meyers PA (2001) How effective is dose-intensive/myeloablative therapy against Ewing’s sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan–Kettering experience and a literature review. J Clin Oncol 19:870-80
  53. Ladenstein R, Lasset C, Pinkerton R et al (1995) Impact of megatherapy in children with high-risk Ewing’s tumors in complete remission: a report from the BMT solid tumor registry. Bone Marrow Transplant 15:697-05
  54. Laurence V, Peirga JY, Barthier S et al (2005) Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor. Am J Clin Oncol 28:301-09 CrossRef
  
• 作者单位：Paul J. Chuba (1)
  
  1. Department of Radiation Oncology, St. John Providence Health System, 11800 E. 12 Mile Road, Warren, MI, 48093, USA
  

文摘

Patients diagnosed with Ewing sarcoma family of tumors (ESFT) commonly require multimodality therapy including radiation therapy, in addition to surgery and chemotherapy, to achieve optimal outcomes. In most cases, a specific genetic defect with a translocation t(11:22)(q24;q12) corresponding to fusion between the EWS gene and an ETS proto-oncogene is present. The Intergroup Ewing Sarcoma Studies (IESS) Studies, the CESS studies, and the Euro-Ewing studies, among others, have helped to define the efficacy of chemotherapy agents, as well as the radiation therapy backbone for ESFT used today. The relative effectiveness of surgery, radiation therapy, and combinations of these local control modalities continue to be defined in specific clinical situations and body sites. Important late effects of radiation therapy may include pneumonitis, radiation cystitis, and second malignancy. Promising for the future may be new chemotherapeutic agents, improved radiation techniques including proton radiation therapy, and possibly myeloablative strategies.